Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCLAlexey V. Danilov, Adrian Wiestner, Weiyun Z. Ai et al.|Hematological Oncology|2023Cited by 0